Real-World Data Drives CAR T Treatment Decisions
Payers and providers use real-world data to identify high-performing treatment centers and support value-based contracting arrangements.
In 2017, the first two CAR T-cell therapies, Kymriah and Yescarta, were approved, transforming blood cancer treatment.
- Kymriah (tisagenlecleucel)
- Yescarta (axicabtagene ciloleucel)
Since then, these therapies have been approved for additional indications and five new CAR T-cell therapies have emerged.
Author's summary: Real-world data informs CAR T treatment decisions.